Zeng Zesheng, Xu Shengen, Wang Dingting, Qin Gang
Department of Otolaryngology Head and Neck Surgery, the Affiliated Hospital of Southwest Medical University, Luzhou, 646000, China.
Syst Rev. 2022 Nov 19;11(1):247. doi: 10.1186/s13643-022-02123-y.
BACKGROUND: Previous studies have investigated the prognostic value of the systemic immune-inflammation index (SII) in nasopharyngeal carcinoma (NPC). However, the results have been inconsistent. Therefore, this study aims to investigate the prognostic significance of SII in NPC through a meta-analysis. METHODS: The PubMed, Web of Science, Embase, and Cochrane Library databases were thoroughly searched. The pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated to evaluate the prognostic value of the SII for survival outcomes. RESULTS: A total of six studies comprising 2169 patients were included in the meta-analysis. Pooled analyses indicated that a high SII was significantly associated with worse overall survival (OS) (HR = 1.69, 95% CI = 1.36-2.09, P < 0.001) and progression-free survival (PFS) (HR = 1.60, 95% CI = 1.29-1.98, P < 0.001) in patients with NPC. Subgroup analysis showed that SII was a significant prognostic marker for PFS but not for OS in NPC. CONCLUSION: Our meta-analysis demonstrated that a high SII could be an efficient prognostic indicator of OS and PFS in NPC. In our opinion, SII could be used to predict long-term and short-term outcomes in patients with NPC. Furthermore, we suggest that SII be applied to help individual patients with NPC assess the prognostic risk. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42022321570.
背景:既往研究探讨了全身免疫炎症指数(SII)在鼻咽癌(NPC)中的预后价值。然而,结果并不一致。因此,本研究旨在通过荟萃分析探讨SII在NPC中的预后意义。 方法:全面检索了PubMed、Web of Science、Embase和Cochrane图书馆数据库。计算合并风险比(HR)及95%置信区间(CI),以评估SII对生存结局的预后价值。 结果:荟萃分析共纳入6项研究,包含2169例患者。合并分析表明,NPC患者中高SII与较差的总生存期(OS)(HR = 1.69,95%CI = 1.36 - 2.09,P < 0.001)和无进展生存期(PFS)(HR = 1.60,95%CI = 1.29 - 1.98,P < 0.001)显著相关。亚组分析显示,SII是NPC患者PFS的显著预后标志物,但不是OS的预后标志物。 结论:我们的荟萃分析表明,高SII可能是NPC患者OS和PFS的有效预后指标。我们认为,SII可用于预测NPC患者的长期和短期结局。此外,我们建议应用SII来帮助NPC患者个体评估预后风险。 系统评价注册:PROSPERO CRD42022321570。
Med Oral Patol Oral Cir Bucal. 2024-11-1
J Cancer Res Clin Oncol. 2023-3
Cancer Manag Res. 2022-2-25